Aliskiren: first direct renin inhibitor for essential hypertension

Aliskiren (Rasilez) is the first of a new class of antihypertensive agents, the direct renin inhibitors. Here, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Professor Sever comments on its potential place in the treatment of hypertension. Copyright © 2008 Wiley Interface Ltd